From (Tool)Bench to Bedside: The Potential of Necroptosis Inhibitors

被引：18

作者：

Gardner, Christopher R. ^{[1
,2
]}

Davies, Katherine A. ^{[1
,2
]}

Zhang, Ying ^{[1
,2
]}

Brzozowski, Martin ^{[1
,2
,3
]}

Czabotar, Peter E. ^{[1
,2
]}

Murphy, James M. ^{[1
,2
]}

Lessene, Guillaume ^{[1
,2
,4
]}

机构：

[1] Walter & Eliza Hall Inst Med Res, Parkville, VIC 3052, Australia

[2] Univ Melbourne, Dept Med Biol, Parkville, VIC 3052, Australia

[3] Bio21 Inst, 30 Flemington Rd, Parkville, VIC 3052, Australia

[4] Univ Melbourne, Dept Pharmacol & Therapeut, Parkville, VIC 3052, Australia

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2023年 / 66卷 / 04期

基金：

澳大利亚国家健康与医学研究理事会;

关键词：

MIXED-LINEAGE KINASE; DOMAIN-LIKE PROTEIN; CELL-DEATH; PSEUDOKINASE MLKL; HIGHLY POTENT; CHEMICAL INHIBITOR; CASPASE INHIBITOR; DISTINCT ROLES; DISCOVERY; RIPK3;

D O I：

10.1021/acs.jmedchem.2c01621

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Necroptosis is a regulated caspase-independent form of necrotic cell death that results in an inflammatory phenotype. This process contributes profoundly to the pathophysiology of numerous neurodegenerative, cardiovascular, infectious, malignant, and inflammatory diseases. Receptor-interacting protein kinase 1 (RIPK1), RIPK3, and the mixed lineage kinase domain-like protein (MLKL) pseudokinase have been identified as the key components of necroptosis signaling and are the most promising targets for therapeutic intervention. Here, we review recent developments in the field of small-molecule inhibitors of necroptosis signaling, provide guidelines for their use as chemical probes to study necroptosis, and assess the therapeutic challenges and opportunities of such inhibitors in the treatment of a range of clinical indications.

引用

页码：2361 / 2385

页数：25

共 50 条

[41] From bench to bedside
Trümper, L
MEDIZINISCHE KLINIK, 2005, 100 (01) : 53 - 53
[42] From bench to bedside
Karen Kreeger
Nature, 2003, 424 (6952) : 1090 - 1091
[43] From bench to bedside
Colin L Verdant
Critical Care, 16
[44] From bench to bedside
Filipp, Fabian
Fischer, Alain
EMBO REPORTS, 2007, 8 (05) : 429 - 432
[45] From bench to bedside
Lorenz Trümper
Medizinische Klinik, 2005, 100 : 53 - 53
[46] From bench to bedside
Eckelman, WC
Vera, DR
NUCLEAR MEDICINE AND BIOLOGY, 2003, 30 (08) : 793 - 794
[47] From Bench to Bedside
Dwortzan, Mark
IEEE PULSE, 2011, 2 (04) : 55 - 58
[48] FROM BENCH TO BEDSIDE
WILLERSON, JT
CIRCULATION, 1994, 89 (06) : 2488 - 2488
[49] Bench to bedside - Bedside to bench: Preclinical determination of the potential pharmacological activities of vandetanib in the clinic
Ryan, A. J.
Odedra, R.
James, N.
Ratcliffe, K.
Marshall, G.
Howard, Z.
Jackson, L.
Baker, D.
Smith, N.
Brave, S. R.
EJC SUPPLEMENTS, 2008, 6 (12): : 184 - 184
[50] Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside
Fujimura, Taku
Fujisawa, Yasuhiro
Kambayashi, Yumi
Aiba, Setsuya
CANCERS, 2019, 11 (09)

← 1 2 3 4 5 →